**Major Liver Resection, Systemic Fibrinolytic Activity, and the Impact of Tranexamic Acid**

**Running head**: Fibrinolysis during Liver Resection

Paul J Karanicolas MD PhD1,2, Yulia Lin MD3,4, Jordan Tarshis MD5,6, Calvin HL Law MD1,2, Natalie G Coburn MD1,2, Julie Hallet MD1,2, Barto Nascimento MD1,2, Janusz Pawliszyn PhD7, Stuart A. McCluskey MD PhD6,8

1. Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON
2. Department of Surgery, University of Toronto, Toronto, ON
3. Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, ON
4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON
5. Department of Anesthesia, Sunnybrook Health Sciences Centre, Toronto, ON
6. Department of Anesthesia, University of Toronto, Toronto, ON
7. Department of Chemistry, University of Waterloo, Waterloo, ON
8. Department of Anesthesia and Pain Management, University Health Network, Toronto, ON

**Presented at:** The Canadian Surgical Forum, Quebec City, Canada, Sept 19 2015

**Corresponding Author**: Dr. Paul Karanicolas

Hepatobiliary, pancreatic, and gastrointestinal surgical oncology

Sunnybrook Health Sciences Centre - Odette Cancer Centre

2075, Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada

Tel: 1 (416) 480-4774; Fax: 1 (416) 480-6002; paul.karanicolas@sunnybrook.ca

**Abstract**

**Background**

Hyperfibrinolysis may occur due to systemic inflammation or hepatic injury that occurs during liver resection. Tranexamic Acid (TXA) is an antifibrinolytic agent that decreases bleeding in various settings, but has not been well studied in patients undergoing liver resection.

**Methods**

In this prospective, phase II trial, 18 patients undergoing major liver resection were sequentially assigned to one of three cohorts: (1) Control (no TXA); (2) TXA Dose I- 1 g bolus followed by 1 g infusion over 8 hours; (3) TXA Dose II- 1 g bolus followed by 10 mg/kg/hr until the end of surgery. Serial blood samples were collected for thromboelastography (TEG), coagulation components and TXA concentration.

**Results**

No abnormalities in hemostatic function were identified on TEG. PAP complex levels increased to peak at 1106 ug/L (normal 0-512 ug/L) following parenchymal transection, then decreased to baseline by the morning following surgery. TXA reached stable, therapeutic concentrations early in both dosing regimens. There were no differences between patients based on TXA.

**Conclusions**

There is no thromboelastographic evidence of hyperfibrinolysis in patients undergoing major liver resection. TXA does not influence the change in systemic fibrinolysis; it may reduce bleeding through a different mechanism of action.

**Keywords**: Blood Transfusion, Fibrinolysis, Hemostasis, Hepatectomy, Tranexamic Acid

**Registered with ClinicalTrials.gov: NCT01651182**

**INTRODUCTION**

Liver resection is the optimal treatment for patients with primary or metastatic liver malignancies, benign liver tumors, and some biliary diseases.[1-5](#_3znysh7) Despite many technical advances, intraoperative bleeding remains a problem during liver resection with 30-40% of patients receiving perioperative blood transfusions.[6-8](#_4d34og8) Blood transfusion carries several risks, including transfusion-transmitted viruses, transfusion-related acute lung injury, transfusion-associated circulatory overload, acute hemolytic transfusion reactions, bacterial contamination and severe allergic reactions.[9](#_3rdcrjn) In addition, bleeding and blood transfusion are risk factors for postoperative morbidity and in some reports, long-term cancer recurrence.[6](#_4d34og8),[10-22](#_26in1rg) Furthermore, blood products are sometimes scarce and associated with appreciable expense. Thus, there is compelling rationale to reduce blood loss and blood transfusion as much as possible in patients undergoing liver resection.

Hemostatic function is determined by the interaction of the vascular wall, platelets, coagulation factors, and fibrinolytic function.[7](#_2s8eyo1),[23](#_2bn6wsx),[24](#_qsh70q) The hemostatic system may be abnormal in patients who have compromised liver function and this may contribute to excessive bleeding during liver surgery. In particular, primary hyperfibrinolysis may occur as a result of the systemic inflammatory effect of surgery or due to hepatic injury that occurs during liver surgery. Hyperfibrinolysis may be inhibited by the administration of antifibrinolytic agents including plasmin inhibitors (aprotinin) and plasminogen inhibitors (lysine analogues - tranexamic acid (TXA) and episilon aminocaproic acid (EACA)). Although aprotinin appears to be effective at reducing bleeding, its use has been associated with an increased risk of death and renal compromise when compared to the lysine analogs.[25](#_3as4poj),[26](#_1pxezwc)

TXA decreases bleeding in various settings including multisystem trauma, orthopedic surgery, spine surgery, cardiopulmonary bypass, and liver transplantation.[7](#_2s8eyo1),[27-31](#_49x2ik5) It has not been well studied in patients undergoing liver resection, and it is rarely used in that setting.[32](#_ihv636),[33](#_32hioqz) Our objectives were to characterize the impact of liver resection on systemic fibrinolysis, and to define the impact of TXA at two different doses on fibrinolysis.

# METHODS

We conducted a prospective, open label, phase II trial examining the impact of TXA at two doses on fibrinolysis during major liver resection. The protocol was approved by the Sunnybrook Health Sciences Centre Research Ethics Board and registered with ClinicalTrials.gov (NCT01651182).

Patient Eligibility

Patients over the age of 18 undergoing anticipated open or laparoscopic major liver resection (greater than two segments) were approached and invited to participate in the trial. Patients were excluded if they were scheduled for hepatectomy associated with vascular or biliary reconstruction, had a platelet count less than 100,000 x 109/L, severe anemia (hemoglobin level less than 90 g/L), documented arterial or venous thrombosis in the past three months, known disseminated intravascular coagulation, severe renal insufficiency (CrCl < 30 mL/min), history of seizure disorder, hypersensitivity to TXA or any of the ingredients, were pregnant or lactating, unable to receive blood products, had received chemotherapy within 4 weeks of scheduled operation, were taking anticoagulants, direct thrombin inhibitors or thrombolytic therapy within the last week, or were previously enrolled in this study. Patients were screened in the surgical clinic at the time of surgical consent and provided a separate consent to participate in this trial.

Interventions

Cohorts of 6 subjects were enrolled sequentially to one of the three regimens: (1) Control (no TXA); (2) TXA Dose I - 1 g bolus followed by 1 g infusion over 8 hours initiated 15 minutes after the bolus dose; and (3) TXA Dose II: -1 g bolus followed by 10 mg/kg/hr initiated 15 minutes after the bolus dose until the end of surgery. Dose I was selected based on the CRASH-2 trial, in which 20,000 trauma patients worldwide were randomly assigned to TXA or placebo.[27](#_49x2ik5) This dose was effective at reducing death due to bleeding and was not associated with increased adverse events. The higher dose, Dose II, is more frequently used in liver transplant surgery, with no increase in thrombosis, reoperation or mortality in this setting.[34](#_1hmsyys)

General anaesthesia and liver resection proceeded according to standard institutional practices with no other modifications for the purposes of this trial. Clinicians were not permitted to utilize other systemically administered antifibrinolytic agents. All patients had a central line with the central venous pressure (CVP) maintained as low as possible during anaesthesia.[35-37](#_41mghml) Liver transection was accomplished using the Kelly-crush technique with portal inflow clamping (the Pringle maneuver) at the surgeons’ discretion. Transfusion of blood products (red blood cells, fresh frozen plasma, platelets, or cryoprecipitate) was guided by a standardized restrictive protocol. Red blood cells were transfused for Hgb < 70 g/L; or Hgb 70-90 g/L based on medical judgment with an indication provided by the transfusing clinician (coronary ischemia, hemodynamic instability, ongoing blood loss, etc). Red blood cells were transfused one unit a time in non-bleeding patients. Fresh frozen plasma was transfused for INR > 1.5 with clinically active bleeding. Platelets were transfused only if the patient was clinically bleeding with platelet count < 50 x 109/L and cryoprecipitate only if patient was bleeding with fibrinogen < 1.0 g/L.

Outcomes

Routine clinical data were collected including patient demographics, extent of liver resection, intraoperative blood loss, transfusions, and postoperative complications until discharge.

Blood samples were collected at four time points to determine the extent of fibrinolysis: (1) baseline – immediately after induction; (2) after liver mobilization, prior to transection; (3) after liver transection; and (4) post-operatively, 24 hours following induction. At each of these times two 5 ml samples of arterial blood were collected into standard citrated blood tubes. The following laboratory parameters were measured: INR, PTT, fibrinogen, and plasmin-antiplasmin (PAP) complex. PAP is a relatively stable complex of plasmin (the key enzyme of the fibrinolytic system) and its inhibitor α2-antiplasmin. The plasma PAP concentration is thus a measure of the current activity of the fibrinolytic system. Expected normal values for PAP complex levels are 0–514 ug/L (2.5–97.5% percentiles).

A 2 mL sample was collected from each patient for thromboelastography (TEG) assessment, which assesses the viscoelastic properties of whole blood clotting under low shear conditions. TEG samples were processed within 1 h of blood draw at 37 °C using a Rotational Thromboelastometry (TEG) delta instrument (TEM International, Munich, Germany). The methodology and the parameters of TEG have been described previously in detail[38](#_3fwokq0). Two separate TEG assays were performed for each patient: (1) the EXTEM assay activates haemostasis via the physiological activator tissue factor and is a screening test for extrinsic haemostatic function; (2) the FIBTEM assay eliminates the platelet contribution of clot formation by inhibiting the platelets irreversibly with cytochalasin D. A comparison of EXTEM and FIBTEM allows for the detection of fibrinogen deficiency or fibrin polymerization disorders.

Blood samples were collected in all patients for pharmacokinetic analysis at the following times: baseline (immediately prior to drug bolus), during drug infusion at time 0, 30, 60, and every 120 min after initiation of the infusion, and during the drug elimination phase after discontinuation of drug infusion at time 0, 4, and 24 hours. Blood samples were collected in standard 2.5 ml citrated tubes (Vacutainer, Becton Dickson, Franklin Lakes, NJ, USA), centrifuged and the plasma supernatant stored at -70°C within 6 hours of sampling. TXA concentration was measured using solid phase microextraction techniques and Tandem liquid chromatography-mass spectrometry as previously described[39](#_1v1yuxt),[40](#_4f1mdlm).

Statistical Analysis

Descriptive statistics were used to summarize patient demographics and clinical outcomes. Categorical variables were reported as absolute values (N) and frequencies (%) and compared between groups using Fisher’s exact test (F-E). Continuous variables were reported as medians and interquartile ranges (IQRs) and Kruskal-Wallis (K-W) testing was used to detect statistically significant differences between the three groups. Non-linear mixed effects modeling explored the extent of fibrinolysis that occurs during liver resection, the impact of TXA on fibrinolysis, and the impact of TXA dosing regimen on TXA plasma concentration.

The analytical plan was to select the most appropriate dose of TXA for future study based on the inhibition of hyperfibrinolysis using TEG or PAP complexes. In the absence of differences in either of these measures, the dose was selected as the minimum required to achieve a stable plasma TXA concentration of 10 mcg/ml; the concentration demonstrated in vitro to be required to completely inhibit fibrinolysis. The sample size calculation was based on the pharmacokinetic modeling; with six patients in each group the pharmacokinetic profile of both regimens could be confidently differentiated using pharmacokinetic computer modeling (NONEM, GloboMax LLC, Hanover, MD).

**RESULTS**

The majority of patients (16 of 18) underwent liver resection for colorectal cancer liver metastases, with only one patient diagnosed with hepatocellular carcinoma and one with cholangiocarcinoma (Table 1). Operations were extensive; including extended right hepatectomy (5), right hepatectomy (4), left hepatectomy (1), and a variety of non-anatomic resections encompassing greater than two segments. Median operative time was 291 minutes, including 67 minutes of parenchymal transection time. Surgeons used intermittent inflow occlusion (Pringle maneuver) in the majority of cases (15).

 Clinical outcomes were favorable, with no mortalities and only one patient receiving red blood transfusion, while no patients received other blood products (Table 2). There were no major complications. Notably, there were no thromboembolic events or seizures noted during the study period. Median length of stay was 5 days with a range of 3-18 days. Two patients were readmitted after discharge, neither with bleeding or thromboembolic events.

 TEG analysis revealed normal whole blood clotting parameters with no evidence of hyperfibrinolysis, and no differences between control and TXA treatment groups (Supplemental Table).

 INR increased significantly in patients by the end of parenchymal transection, and continued to rise by the morning of post-operative day 1 (POD1) (Figure 1). Fibrinogen levels decreased steadily during operation, reaching a trough of 2.77 ± 0.71 g/L after parenchymal division then increasing by the morning of POD1, although they did not return to baseline (Figure 2). PAP complex levels mirrored this trend, increasing steadily to peak at more than twice normal (1106 ± 407 µg/L) following parenchymal transection then decreasing by the following morning (Figure 3). There were no differences noted in any of these measurements in patients treated with TXA at either dose.

 Plasma TXA concentration increased rapidly immediately following the bolus to peak at 204 ± 36 µg/mL. After approximately one hour during TXA infusion, the concentration reached a steady concentration of 37 ± 3 µg/mL in the Dose I group and 70 ± 12 µg/mL in the Dose II group (Figure 4). All TXA was eliminated by 24 hours following surgery.

**DISCUSSION**

 This trial examining hemostatic function during major liver resection demonstrated no evidence of hyperfibrinolysis by thromboelastography. However, fibrinogen levels decreased and PAP, a marker of fibrinolysis, increased modestly during liver resection. The use of TXA employing the dose used in the CRASH-2 study or the dose routinely used in liver transplantation had no detectable impact of fibrinogen levels or degradation. Importantly, the serum concentration of TXA was maintained throughout the perioperative period at concentration in excess of 10 mcg/ml; the concentration demonstrated in vitro to be required to completely inhibit fibrinolysis.

Liver resection remains a major undertaking, with hepatic dysfunction combined with a profound systemic inflammatory response. These two factors have the potential to substantially alter the systemic hemostatic function through a number of mechanisms, potentially including activation of hyperfibrinolysis. Conventional laboratory measures of hemostatic function including INR and PTT are frequently elevated following major liver resection due to impaired hepatic synthetic function, and are not accurate measures of hemostatic function in this setting. Furthermore, elevations in INR typically occur 24-48 hours following resection, whereas the majority of bleeding (and hence the opportunity for intervention) generally occurs intraoperatively. In this study, INR was increased slightly 24 hours following liver resection. Similarly, although fibrinogen levels decreased slightly during the course of hepatic transection, they are not sensitive enough to be relied upon for assessment of fibrinolytic function during major surgery.

 Thromboelastometry has been studied in a number of settings where hyperfibrinolysis may occur, including multisystem trauma[41](#_2u6wntf). A major advantage of TEG is its ability to provide real-time information regarding a patient’s hemostatic function. However, massive near-fatal trauma is required to produce detectable changes in TEG, so it may not be sensitive enough to identify patients undergoing elective surgery with moderate hyperfibrinolysis who may benefit from antifibrinolytic therapy[42](#_19c6y18). In this study of patients undergoing major liver resection, TEG failed to identify any abnormalities in fibrinolytic function.

 In contrast, PAP complex levels may be elevated in patients with modest, but clinically significant hyperfibrinolysis. In one study of patients with multisystem trauma, PAP complex levels were significantly elevated in 57% of patients with moderate or severe injuries, while TEG detected abnormalities in only 5% of patients[42](#_19c6y18). TEG detected clot lysis only when PAP complex levels were increased to 30 times normal. Furthermore, PAP complex levels were independently associated with need for red blood cell transfusion, ventilator-free days, length of hospitalization, and 28-day mortality. In our study, PAP complex levels increased modestly by the end of transection. PAP complex levels had returned to baseline by the morning following surgery, indicating that the fibrinolytic activity is transient.

 The transient fibrinolysis that occurs around the time of liver resection presents a potential opportunity to intervene and improve hemostatic function, thereby reducing blood loss and transfusion. TXA has been well studied in various settings including multisystem trauma, orthopedic surgery, spine surgery, cardiopulmonary bypass, and liver transplantation.[7](#_2s8eyo1),[27-31](#_49x2ik5) The most compelling evidence of the effectiveness of TXA comes from the large multicentred, multi-national CRASH-2 trial.[27](#_49x2ik5) This prospective randomized controlled trial included more than 20,000 patients with multisystem trauma in 40 countries. Patients randomized to receive TXA within one hour of trauma had a 32% reduction in death due to bleeding compared to placebo.

In a recent meta-analysis of 95 surgical randomized controlled trials (N=7838 patients), TXA reduced the probability of receiving a blood transfusion by one third (risk ratio 0.62, 95% confidence interval 0.58 to 0.65; P<0.001).[43](#_37m2jsg) The majority of these trials were in cardiac and orthopaedic surgery however, where the mechanism of bleeding is significantly different than abdominal surgery. Four small trials have been performed in patients having liver transplantation; TXA did not result in significant reduction of allogenic blood transfusion, although the confidence interval was wide and there was a trend towards improvement.44 Only one randomized controlled trial has examined the role of perioperative parenteral TXA in patients undergoing liver resection.33 Among 212 patients who underwent liver resection, the blood transfusion rate was 16% in the control group and 0% in patients who received preoperative TXA (p < 0.001). This trial included mainly patients undergoing minor liver resection, with only 18% of patients having major liver resection (greater than two segments), and the results have not changed practice in North America32.

The trials included in the meta-analysis all evaluated the impact of TXA on clinical outcomes, but only a few of them examined the impact of TXA on laboratory measures of hemostasis. In one trial of TXA in patients undergoing total hip arthroplasty with concomitant hydroxyethyl starch, patients randomized to the control group demonstrated significant fibrinolysis on TEG, and this effect was attenuated by TXA.45 Two trials have examined the impact of TXA on TEG markers of fibrinolysis in cardiac surgery, yielding conflicting conclusions.46, 47 To our knowledge, none of the trials identified measured the impact of TXA on PAP complex levels.

 In our study, TXA did not impact the extent of fibrinolysis as measured with TEG or PAP complex levels. It is possible that neither of these measures are sensitive enough to detect clinically relevant changes in fibrinolysis that TXA impacts. Another possibility is that TXA acts through a different mechanism that is not accurately assessed by TEG or PAP complexes. Further research is warranted to elucidate the mechanism of action of TXA, and to investigate the impact of other antifibrinolytic agents on the hemostatic system in this setting. Furthermore, given the compelling evidence of TXA’s effectiveness in other settings, trials examining the impact of TXA on clinical outcomes (bleeding and blood transfusion) following liver surgery would be beneficial.

Our study provides pharmacokinetic information that may be used to design future trials of TXA in patients undergoing liver resection. The two most commonly used doses of TXA are 1 g bolus followed by 1 g over 8 hours (from the CRASH-2 trial) and 1 g bolus followed by 10 mg/kg/hr in liver transplantation studies.[27](#_49x2ik5),43  In a meta-regression analysis, the effectiveness of TXA was stable over a wide range of doses, suggesting that the impact of TXA is not dose-dependent at the concentrations used clinically. In contrast, more complications (most notably seizures) were observed at higher doses. The plasma tranexamic acid concentration reported to inhibit fibrinolysis *in vitro* is 10 µg/mL in cardiac surgery.48 Thus, our study suggests that a dose of 1 g bolus followed by 1 g over 8 hours is sufficient to inhibit fibrinolysis in this setting.

This study is most limited by the relatively low sample size. It was not powered to identify relationships between extent of fibrinolysis and clinical outcomes; although this would be an interesting area for future study. We did not include a comparator group of patients undergoing other types of operations, so it is difficult to determine the impact of the liver resection on fibrinolysis compared with any other major operative interventions.

In summary, this trial demonstrated no evidence of hyperfibrinolysis during liver resection by thromboelastography and only modest increases in PAP, a more sensitive marker of fibrinolysis. Neither of these hemostatic parameters was altered by TXA, despite serum concentrations in excess of 10 mcg/ml; the concentration demonstrated in vitro to be required to completely inhibit fibrinolysis. Although there does not appear to be substantial systemic hyperfibrinolysis in patients undergoing major liver resection, there may be excessive fibrinolysis locally at the parenchymal surface, and inhibition of this process with TXA may strengthen clot. Further research is warranted to elucidate the mechanism of action of TXA and to examine the impact of TXA on clinical outcomes (bleeding and blood transfusion) following liver surgery.

**Declaration of Interests**

All authors have no relevant conflicts of interest to declare.

**Funding**

This work was supported by The University of Toronto Grant Miller Cancer Research Grant. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Author’s Contributions**

PJK – Study design, patient recruitment, data collection, data analysis, writing first draft of manuscript, critical revisions, approved final version

YL – Study design, data analysis, critical revisions, approved final version

JT – Study design, data analysis, critical revisions, approved final version

CHL – Study design, patient recruitment, data collection, critical revisions, approved final version

NGC – Study design, patient recruitment, data collection, critical revisions, approved final version

JH – Study design, patient recruitment, data collection, critical revisions, approved final version

BN – Study design, data analysis, critical revisions, approved final version

JP – Data collection, data analysis, critical revisions, approved final version

SAM – Study design, data analysis, critical revisions, approved final version

**Acknowledgements**

We are grateful to the research staff and students who contributed tirelessly to the conduct of this trial: Jenny Lam-McCulloch, Brittany Buck, Margaret Hamel-Smith, Victoria Zuk, Florence Hui, Madeline Lemke, Nikita Looby, Tijana Vasiljevic, Nathaly Reyes Garcés, and Barbara Bojko.

**REFERENCES**

1. Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. Ann Surg. 2000;232:763-76.

2. Lin TY, Lee CS, Chen KM, Chen CC. Role of surgery in the treatment of primary carcinoma of the liver: a 31-year experience. Br J Surg. 1987;74:839-42.

3. Man K, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg. 1997;226:704-11; discussion 11-3.

4. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698-708.

5. Ramos E, Dalmau A, Sabate A, Lama C, Llado L, Figueras J, Jaurrieta E. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transpl. 2003;9:1320-7.

6. Alkozai EM, Lisman T, Porte RJ. Bleeding in liver surgery: prevention and treatment. Clin Liver Dis. 2009;13:145-54.

7. Jarnagin WR, Gonen M, Maithel SK, Fong Y, D'Angelica MI, Dematteo RP, Grant F, Wuest D, Kundu K, Blumgart LH, Fischer M. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg. 2008;248:360-9.

8. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, DeMatteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg. 2003;237:860-70.

9. Mayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA, Wolfgang CL, Schulick RD, Choti MA, Pawlik TM. Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford). 2011;13:473-82.

10. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256:235-44.

11. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006:CD005033.

12. Bui L, Smith A, Bercovici M, Szalai J, Hanna S. Minimising blood loss and transfusion requirements in hepatic resection. HPB. 2002;4:5-10.

13. Gozzetti G, Mazziotti A, Grazi GL, Jovine E, Gallucci A, Gruttadauria S, Frena A, Morganti M, Ercolani G, Masetti M. Liver resection without blood transfusion. Br J Surg. 1995;82:1105-10.

14. Heiss MM, Mempel W, Delanoff C, Jauch KW, Gabka C, Mempel M, Dieterich HJ, Eissner HJ, Schildberg FW. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol. 1994;12:1859-67.

15. Jamieson GG, Corbel L, Campion JP, Launois B. Major liver resection without a blood transfusion: is it a realistic objective? Surgery. 1992;112:32-6.

16. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, Dematteo RP. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249:617-23.

17. Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA, Staley CA 3rd, Kooby DA. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol. 2011;18:1327-34.

18. Kusano T, Sasaki A, Kai S, Endo Y, Iwaki K, Shibata K, Ohta M, Kitano S. Predictors and prognostic significance of operative complications in patients with hepatocellular carcinoma who underwent hepatic resection. Eur J Surg Oncol. 2009;35:1179-85.

19. Rees M, Plant G, Wells J, Bygrave S. One hundred and fifty hepatic resections: evolution of technique towards bloodless surgery. Br J Surg. 1996;83:1526-9.

20. Ryan JA, Faulkner DJ. Liver resection without blood transfusion. Am J Surg. 1989;157(5):472-5.

21. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion. 1995;35:760-8.

22. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-91.

23. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250-8.

24. Porte RJ, Knot EA, Bontempo FA. Hemostasis in liver transplantation. Gastroenterology. 1989;97:488-501.

25. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-31.

26. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011:CD001886.

27. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23-32.

28. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009;123:687-96.

29. Karkouti K, Rampersaud Y, McCluskey S, Evans L, Ghannam M, Mahomed N. Blood conservation in elective spine surgery. Can J Anaesth. 2002;49:A12.

30. Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, Liu M, Chen L, Li L. Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesth Analg. 2012;115:239-43.

31. Wong J, El Beheiry H, Rampersaud YR, Lewis S, Ahn H, De Silva Y, Abrishami A, Baig N, McBroom RJ, Chung F. Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg. 2008;107:1479-86.

32. Truong JL, Cyr DP, Lam-McCulloch J, Cleary SP, Karanicolas PJ. Consensus and controversy in hepatic surgery: A survey of Canadian surgeons. J Surg Oncol. 2014;110:947-51.

33. Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, P'eng FK. Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy. Ann Surg. 2006;243:173-80.

34. Dalmau A, Sabaté A, Koo M, Bartolomé C, Rafecas A, Figueras J, Jaurrieta E. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. Liver Transpl. 2004;10:279-84.

35. Giordano C, Deitte LA, Gravenstein N, Rice MJ. What is the preferred central venous pressure zero reference for hepatic resection? Anesth Analg. 2010;111:660-4.

36. McNally SJ, Revie EJ, Massie LJ, McKeown DW, Parks RW, Garden OJ, Wigmore SJ. Factors in perioperative care that determine blood loss in liver surgery. HPB (Oxford). 2012;14:236-41.

37. Rahbari NN, Koch M, Zimmermann JB, Elbers H, Bruckner T, Contin P, Reissfelder C, Schmidt T, Weigand MA, Martin E, Büchler MW, Weitz J. Infrahepatic inferior vena cava clamping for reduction of central venous pressure and blood loss during hepatic resection: a randomized controlled trial. Ann Surg. 2011;253:1102-10.

38. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008;106:1366-75.

39. Bojko B, Vuckovic D, Cudjoe E, Hoque ME, Mirnaghi F, Wąsowicz M, Jerath A, Pawliszyn J. Determination of tranexamic acid concentration by solid phase microextraction and liquid chromatography-tandem mass spectrometry: first step to in vivo analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:3781-7.

40. Sharma V, Fan J, Jerath A, Pang KS, Bojko B, Pawliszyn J, Karski JM, Yau T, McCluskey S, Wąsowicz M. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia. 2012;67:1242-50.

41. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost. 2007;5:289-95.

42. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11:307-14.

43. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.

44. Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009052.

45. Na HS, Shin HJ, Lee YJ, Kim JH, Koo KH, Do SH. The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis. Anaesthesia. 2016;71:67-75.

46. Kuitunen AH, Suojaranta-Ylinen RT, Kukkonen SI, Niemi TT. Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery. Blood Coagul Fibrinolysis. 2006;17:639-45.

47. Chakravarthy M, Muniraj G, Patil S, Suryaprakash S, Mitra S, Shivalingappa B. A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery. Ann Card Anaesth. 2012;15:105-10.

48. Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver WC, Sarpal RS, Oyen LJ, Ereth MH. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg. 2001;92:1131-6.

**Tables**

**Table 1.** Baseline characteristics of included patients

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total****(18)** | **Control****(6)** | **TXA Dose I****(6)** | **TXA Dose II****(6)** |
| **Age,** Median (IQR) | 65 (60-69) | 68 (61-73) | 66 (63-69) | 62 (54-68) |
| **K-W p-value** | 0.59 |
| **Male,** N (%) | 10 (56) | 4 (67) | 3 (50) | 3 (50) |
| **F-E p-value** | 1.00 |
| **Weight – kg,** Median (IQR) | 75 (60-84) | 76 (60-84) | 82 (79-86) | 62 (51-75) |
| **K-W p-value** | 0.20 |
| **Diagnosis,** N (%) |  |  |  |  |
|  Colorectal Metastases | 16 (89)  | 6 (100) | 5 (83) | 5 (83) |
|  Hepatocellular Carcinoma | 1 (6) | 0 (0) | 1 (17) | 0 (0) |
|  Cholangiocarcinoma | 1 (6) | 0 (0) | 0 (0) | 1 (17) |
| **F-E p-value** | 1.00 |
| **Operation,** N (%) |  |  |  |  |
|  Extended Right Hepatectomy | 5 (28) | 2 (33) | 1 (17) | 2 (33) |
|  Right Hepatectomy | 4 (22) | 1 (17) | 2 (33) | 1 (17) |
|  Left Hepatectomy | 1 (6) | 0 (0) | 0 (0) | 1 (17) |
|  Other | 8 (44) | 3 (50) | 3 (50) | 2 (33) |
| **F-E p-value** | 1.00 |
| **Number of Segments Resected,**Median (IQR) | 4 (3-5) | 4 (4-4) | 5 (3-5) | 4 (3-5) |
| **K-W p-value** | 0.87 |
| **Operative Time – minutes,** Median (IQR) | 291(265-330) | 268 (184-290) | 313(275-350) | 306 (283-330) |
| **K-W p-value** | 0.32 |
| **Parenchymal Transection Time – minutes,** Median (IQR) | 67 (47-105) | 60 (49-119) | 93 (72-122) | 64 (40-87) |
| **K-W p-value** | 0.54 |
| **Inflow Occlusion (Pringle),** N (%) | 15 (83) | 5 (83) | 6 (100) | 4 (67) |
| **F-E p-value** | 0.74 |
| **Intraoperative Blood Loss – mL,** Median (IQR) | 900 (500-1500) | 650 (300-1500) | 1200(500-1450) | 500(400-1000) |
| **K-W p-value** | 0.05\* |

**Table 2.** Clinical outcomes of included patients

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total****(18)** | **Control****(6)** | **TXA Dose I-****(6)** | **TXA Dose II****(6)** |
| **Red Blood Cell Transfusion\*,** N (%) | 1 (6) | 0 (0) | 1 (17) | 0 (0) |
| **F-E p-value** | 1.00 |
| **Complications,** N (%) |  |  |  |  |
|  Confusion | 2 (11) | 0 | 2 (33) | 0 |
|  Fever | 1 (6) | 0 | 0 | 1 (17) |
|  Ileus | 1 (6) | 0 | 1 (17) | 0 |
|  Urinary | 1 (6) | 0 | 0 | 1 (17) |
|  Ascites | 1 (6) | 0 | 1 (17) | 0 |
| **Length of Stay – days,**Median (IQR) | 5 (4-14) | 4 (4-4) | 11 (4-15) | 6 (4-15) |
| **K-W p-value** | 0.11 |
| **Readmission,** N (%) | 2 (11) | 0 | 0 | 2 |
| **F-E p-value** | 0.29 |

\*No other blood products were transfused to any patients

**Figure Legends**

**Figure 1.** Trend in INR values at different time points (error bars represent standard error). Dashed line represents upper limit of normal range (1.10).

**Figure 2.** Trend in fibrinogen values at different time points (error bars represent standard error). Dashed line represents lower limit of normal range (2 g/L).

**Figure 3.** Trend in plasmin-antiplasmin (PAP) complex values at different time points (error bars represent standard error). Dashed line represents upper limit of normal range (512 ug/L).

**Figure 4.** Plasma concentration of TXA at different time points relative to bolus and infusion of TXA in patients (error bars represent standard error). Dashed line represents in-vitro therapeutic level of TXA (10 µg/mL).

****







